Transcript Feedback and updates from New drugs and MDR TB working groups

Elizabeth Gardiner, TB Alliance
Introducing New Tools & Approaches (INAT) - Berlin
November 12, 2010
New Drug Working Group
 Co-Chairs: Mel Spigelman & Bill Bishai
 Members: 140+ including pharmaceutical companies,
TB Alliance, TAG, Community Representative
(Zimbabwe), BMGF
 Subgroups on Clinical Trial Capacity, Biology Targets,
New Candidates, Knowledge & Tools
 Focus: R&D information sharing
 Website with pipeline, blog, videos
 Future: introduction of new drugs
Linkage with INAT
 For WGND
 Information about INAT

Link to INAT website, slides about what INAT is
 Guidance




Who/where is the TB drug market
What patients/countries want
How can products be used
What dose works for uptake
 Help Community Representative deliver the right message to the
audience
 For INAT
 Useful pipeline for INAT
 Go-to for scientific information on new drugs
 Other?
MDR Working Group
 Chair: Ahmer Khan, Indus Hospital
 Members: PIH, WHO/SEARO, WHO/GVA,
Community Representatives (Nigeria & India), Union,
BMGF, Resist-TB, USAID, Eli Lily, PATH
 Subgroups on Research, Infection Control &
Prevention, Drug Management, Diagnostics
 Overseeing & providing guidance on MDR issues
including subgroup topics, GLI, compassionate use,
etc.
Role for INAT
 Should be grounded in framework of RTF
 Need for coordination more than encouragement
 Wants INAT to
 track/disseminate info on all related new tools activities
across Partnership, Department, & TDR, donor-funded
activities (e.g. STREAM study, LPA studies, GenExpert
availability)
 identify sources of information on X, Y & Z (e.g.
diagnostics, Resist-TB, TMC 207)
 Advocate for new tools but through existing structures